Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms
- PMID: 3516393
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms
Abstract
Tumor-associated monoclonal antibodies were radiolabeled with 125I and 131I and given i.v. in pairs to 19 patients 1-26 days prior to surgical excision of primary and metastatic breast, ovarian, and gastrointestinal tumors. For individual patients each monoclonal antibody was designated as specific or nonspecific according to prior immunoperoxidase staining results on the appropriate target neoplastic tissues. Quantitation of antibody uptake was performed on resected normal and neoplastic tissues. Although good tumor:non-tumor ratios were obtained with the specific antibodies (maximal tumor:blood ratio, 35.8:1 at 12 days postadministration), the absolute amount of radiolabel detected in tumors was small (mean value of 0.015% of total injected amount per g of tumor occurring 1 day postadministration). Furthermore, both specific and nonspecific antibodies accumulated in normal lymph nodes to a significant extent (mean value of 0.0026% of total injected amount per g of tissue occurring 1 day postadministration). Knowledge of such data is essential prior to considering therapeutic uses of radiolabeled monoclonal antibodies.
Similar articles
-
Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.Anticancer Res. 1995 May-Jun;15(3):975-84. Anticancer Res. 1995. PMID: 7645989
-
Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.Cancer Res. 1995 Mar 1;55(5):1060-9. Cancer Res. 1995. PMID: 7866989 Clinical Trial.
-
Targeting strategies for cancer radiotherapy.Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s. Clin Cancer Res. 1999. PMID: 10541342
-
Tumor detection using radiolabeled monoclonal antibodies.Crit Rev Clin Lab Sci. 1987;25(4):313-51. doi: 10.3109/10408368709105887. Crit Rev Clin Lab Sci. 1987. PMID: 3322676 Review.
-
Monoclonal antibodies in nuclear medicine.J Nucl Med. 1985 May;26(5):531-7. J Nucl Med. 1985. PMID: 2580961 Review.
Cited by
-
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies.MAbs. 2024 Jan-Dec;16(1):2324485. doi: 10.1080/19420862.2024.2324485. Epub 2024 Mar 4. MAbs. 2024. PMID: 38700511 Free PMC article.
-
Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates.Int J Mol Sci. 2023 Jul 2;24(13):11011. doi: 10.3390/ijms241311011. Int J Mol Sci. 2023. PMID: 37446189 Free PMC article.
-
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.Ther Adv Med Oncol. 2023 Jul 8;15:17588359231183679. doi: 10.1177/17588359231183679. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37435563 Free PMC article. Review.
-
Optimizing the safety of antibody-drug conjugates for patients with solid tumours.Nat Rev Clin Oncol. 2023 Aug;20(8):558-576. doi: 10.1038/s41571-023-00783-w. Epub 2023 Jun 9. Nat Rev Clin Oncol. 2023. PMID: 37296177 Review.
-
The role of acoustofluidics and microbubble dynamics for therapeutic applications and drug delivery.Biomicrofluidics. 2023 Apr 10;17(2):021502. doi: 10.1063/5.0130769. eCollection 2023 Mar. Biomicrofluidics. 2023. PMID: 37153864 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources